EGFR-TKIs治疗晚期非小细胞肺癌缓慢进展后间插治疗模式的临床观察

Intercalated treatment of advanced non-small cell lung cancer patients with gradual progression after failure of EGFR tyrosine kinase inhibitors therapy:a clinical observation

目的探讨间插治疗模式是否可延长经EGFR-TKIs治疗的晚期非小细胞肺癌(NSCLC)缓慢进展后患者的无进展生存期(PFS)。方法收集2009年8月至2014年12月就诊于江苏省肿瘤医院的EGFR-TKIs治疗后缓慢进展的晚期NSCLC患者24例,均采用化疗药物和EGFR-TKIs间插治疗模式进行治疗。比较EGFR-TKIs治疗至缓慢进展的PFS及EGFR-TKIs治疗至间插治疗模式进展后的PFS。随访至2015年4月30日,绘制中位PFS生存曲线图。结果 22例患者可评估中位PFS,EGFRTKIs治疗至缓慢进展的中位PFS为13.3个月,EGFR-TKIs治疗至间插治疗模式进展的中位PFS为24个月(P<0.001)。结论晚期NSCLC患者经EGFR-TKIs治疗后发生缓慢进展时,采用化疗药物和EGFR-TKIs间插治疗模式可显著延长患者的中位PFS。

Objective To observe the PFS （Progression Free Survival） could be extended in advanced NSCLC（ non-small cell lung cancer） patients with gradual progression after failure of EGFR tyrosine kinase in- hibitors therapy by intercalated treatment. Methods 24 advanced NSCLC patients from August 2009 to Decem- ber 2014 were collected after gradual progression treated by EGFR-TKIs. All of these patients were accepted in- tercalated treatment of chemotherapy and EGFR-TKIs, in comparison with the PFS of EGFR TKIs treatment to the gradual progression and the PFS of EGFR TKIs treatment to progression of intercalated treatment. Follow-up visit came to end on April 30th, 2015, the median PFS survival was draun accordingly. Results 22 patients could be evaluated on the basis of PFS. The PFS of EGFR TKIs treatment to the gradual progression was 13.3 months. The PFS of EGFR TKIs treatment to progression of intercalated treatment was 24 months （P 〈 0. 001 ）. Conclusion The PFS could be signally extended in NSCLC patients with gradual progression after failure of EGFR tyrosine kinase inhibitors therapy by intercalated treatment.